Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Angiodynamics, Body Vision, Cue, Femasys, Hemosonics, Invo, Kral Medical, Prism Technologies, Paragon Care, Shockwave Medical, Tandem.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Hipra, M8, Molecular Targeting, Satellos.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Cybin, Enlivex, Ideaya, Immunis, India Globalization, Inimmune, Oculis, Theriva.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Bridgebio, Biohaven, Citius, GC, Harm Reduction, Invectys, Marinus, Merck & Co., Moberg, Nanjing Leads, Redhill, Spero, Transcenta.
Clinical data in the first half of 2023 is up 1.51% compared to the same time period last year. So far in 2023 BioWorld reported on 1,810 drugs in phase I-III, compared to 1,783 in the first half of 2022. The number of trial updates is down 13.6% from the 2,095 in 2021, but more than 2020’s 1,799 and 2019’s 1,477.
Suzhou Ark Biopharmaceutical Co. Ltd. has synthesized 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).
Shanghai Curegene Pharmaceutical Co. Ltd. has synthesized macrocyclic compounds acting as 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).
Taking strides from its start as a Seoul National University laboratory, South Korea’s Cellid Co. Ltd. said July 24 that the MFDS approved an IND for the global phase III trial for its omicron variant-targeting COVID-19 vaccine called AdCLD-CoV19-1 OMI. Approval from the MFDS comes two months after Cellid filed the IND on May 23 for its adenovirus vector platform vaccine “capable of responding quickly to virus mutations,” the company said.
Anbio Biotechnology Ltd. launched the Anbio AF-100S, an automated, compact and affordable fluorescent immunoassay (FIA) solution that it hopes will transform the field of clinical diagnostics and empower healthcare providers. The AF-100S FIA is a handheld point-of-care immunodiagnostic solution that provides rapid, accurate and reliable results for a wide range of analytes.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Advent, Astria, Biophytis, Excision, Hutchmed, Ipsen, Junshi, Pharmala.
RSS
